Shawn Vadala - Mettler
Chief Financial Officer at Mettler-Toledo International
Thanks, Patrick, and good evening, everybody. Sales were $952 million in the quarter, an increase of 16% in local currency. On a U.S. dollar basis, sales increased 18% as currency benefited sales growth by 2% in the quarter. The PendoTECH acquisition contributed approximately 1% to local currency sales growth in the quarter, while we estimate that COVID testing was a headwind of approximately 1% to sales growth. Last year, the benefit in our pipette business from COVID testing labs was particularly strong. On Slide four, we show sales growth by region. Local currency sales increased 20% in the Americas, 10% in Europe and 16% in Asia/Rest of the World. Local currency sales increased 19% in China in the quarter. The next slide shows sales growth by region year-to-date. Local currency sales grew 20% for the nine months with a 21% increase in the Americas, 15% in Europe, and 23% growth in Asia/Rest of World.
On Slide six, we summarize local currency sales growth by product area. For the third quarter, Laboratory sales increased 23%, Industrial increased 12%, with core Industrial up 11% and product inspection up 13%. Food Retail came in worse than we expected with a decline of 19% in the quarter. The next slide shows local currency sales growth by product area year-to-date. Laboratory sales increased 26%, Industrial increased 16%, with core Industrial up 21% and product inspection up 9%. Food Retail declined 1% for the nine-month period. Let me now move to the rest of the P and L, which is summarized on Slide eight. Gross margin in the quarter was 58.4%, a 20 basis point increase over the prior year level of 58.2%. We benefited from volume and pricing which was offset in part by the challenges in the global supply chain, namely higher transportation, logistics and material costs as well as the impact of temporary cost actions we undertook in 2020. R and D amounted to $42.3 million in the quarter, which is a 19% increase in local currency over the prior period. The impact of temporary cost savings undertaken last year and greater project activity contributed to this increase. SG and A amounted to $240.7 million, a 16% increase in local currency over the prior year.
The impact of the temporary cost savings that we undertook last year, higher variable compensation, and increased investments in sales and marketing were the principal factors driving the increase. Adjusted operating profit amounted to $272.8 million in the quarter, a 19% increase over the prior year amount of $230 million. We are pleased with this increase, which reflects very strong sales growth combined with good execution. Adjusted operating margins reached 28.7%, a 20 basis point increase over the prior year level of 28.5%. On a teo-year combined basis, our margins were up 270 basis points as the prior year margin benefited from the cost actions we implemented due to the pandemic. A couple of final comments on the P and L. Amortization amounted to $16 million in the quarter, interest expense was $11.8 million in the quarter, other income in the quarter amounted to $3.3 million primarily reflecting nonservice-related pension income.
Our effective tax rate before discrete items and adjusted for the timing of stock option deductions was 19.5%. Fully diluted shares amounted to $23.4 million in the quarter, which is a 3% decline from the prior year. Adjusted EPS for the quarter was $8.72, a 24% increase over the prior year amount of $7.02. On a reported basis in the quarter, EPS was $8.71 as compared to $6.68 in the prior year. Reported EPS in the quarter includes $0.18 of purchased intangible amortization, $0.02 of restructuring offset by $0.19 due to the difference between our quarterly and annual tax rate due to the timing of stock option exercises. The next slide shows our P and L year-to-date. Local currency sales grew 20%, adjusted operating income increased 35%, with margins up 210 basis points. Adjusted EPS grew 43% on a year-to-date basis. That covers the P and L, and let me now comment on cash flow. In the quarter, adjusted free cash flow amounted to $243.1 million, which is an increase of 19% and on a per share basis as compared to the prior year.
We are very happy with our cash flow generation. DSO was 35 days, which is two days less than the prior year. ITO came in at 4.5 times, which is slightly better than last year. On a year-to-date basis, adjusted free cash flow amounted to $615.3 million, an increase of 48% on a per share basis as compared to the prior year. Let me now turn to guidance. While our end markets remain favorable, forecasting continues to be challenging. There are pockets of uncertainty in the global economy, most notably in China. Furthermore, the widespread challenges within the supply chain and in transportation and logistics and the corresponding inflationary impact also creates uncertainty. Finally, we have seen over the last several months how COVID variance and lockdowns can occur quickly. We recognize the importance of remaining agile and adapting to unexpected changes in the environment.
We are very pleased with our ability to navigate the unprecedented challenges of the last two years, which we believe reflects the strength of our organization. While we remain cautious about factors outside of our control, we feel very good about our growth initiatives and our ability to continue to gain market share and drive margin improvement via our pricing and Stern Drive initiatives. Now let me cover the specifics. For the full year 2021, we now expect local currency sales growth in 2021 and to be approximately 17%. This compares to previous guidance of 15%. We expect full year adjusted EPS to be in the range of $33.35 to $33.40, which is a growth rate of 30%. This compares to previous guidance of adjusted EPS in the range of $32.60 to $32.90. With respect to the fourth quarter, we would expect local currency sales growth to be approximately 8% and expect adjusted EPS to be in the range of $10 to $10.05, a growth rate of 8% to 9%. For the full year 2022, based on our assessment of market conditions today, we would expect local currency sales growth to be approximately 6% and adjusted EPS to be in the range of $37.25 to $37.65.
Using the midpoint of 2021 guidance, this reflects a growth rate of 12% to 13%. Some further comments on 2022 guidance. We expect a slight headwind to sales growth from the impact of COVID testing on our pipette business. We expect interest expense to be approximately $50 million in 2022 in total amortization, including purchase intangible amortization to be $65 million. Purchase intangible amortization is excluded from adjusted EPS and is estimated at $24 million on a pretax basis or $0.79 per share in 2022. In 2022, other income, which is below operating profit, will amount to approximately $13.5 million. This is higher than the $10.7 million expected in 2021 due to an expected increase in pension income. Finally, we assume our effective tax rate before discrete items will be 19.5% in both 2021 and 2022. In terms of free cash flow for 2021, we now estimate it will reach $810 million, which reflects a 29% growth on a per share basis. For 2022, we would estimate free cash flow in the range of $845 million. Cash flow in 2022 is impacted by higher variable compensation payments related to the very strong performance in 2021.
Once we get beyond 2022, we expect free cash flow per share will grow in line with earnings per share and net income conversion will be in the 100% range. We expect to repurchase approximately $1 billion in shares in both 2021 and 2022, which should allow us to maintain a net debt-to-EBITDA ratio of approximately 1.5 times. Some final details on guidance. With respect to the impact of currency on sales growth, we expect currency to increase sales growth by approximately 3% in 2021 and be relatively neutral to sales growth in Q4. In 2022, we would expect currency to decrease sales growth by approximately 1%. In terms of adjusted EPS, currency will benefit growth by approximately 4% in 2021 and be a slight headwind to adjusted EPS growth in 2022. We do not expect currency to impact adjusted EPS in the fourth quarter.
That is it from my side, and I'll now turn it back to Patrick.